Metabolic abnormalities in HIV-infected patients: An update

被引：7

作者：

Brown T.T. ^{[1
]}

Cofrancesco Jr. J. ^{[1
]}

机构：

[1] Baltimore, MD 21287

来源：

Current Infectious Disease Reports | 2006年 / 8卷 / 6期

关键词：

Metformin; Rosiglitazone; Tenofovir; National Cholesterol Education Program; Abacavir;

D O I：

10.1007/s11908-006-0025-5

中图分类号：

学科分类号：

摘要：

In recent years, substantial progress has been made in our understanding of the pathogenesis, risk factors, and treatment of glucose and lipid abnormalities in HIV-infected patients. Newer antiretrovirals, such as abacavir and tenofovir in the nucleoside reverse transcriptase class and atazanavir in the protease inhibitor class, have been shown to improve metabolic profiles compared to other medications. In addition, new information regarding the efficacy of glucose and lipid-lowering medications in HIV-infected patients has become available. It has also been demonstrated that aggressive risk factor modification can reduce the burden of cardiovascular disease in this population. This article reviews these recent advances in order to help providers respond to these important clinical challenges. Copyright © 2006 by Current Science Inc.

引用

页码：497 / 504

页数：7

共 68 条

[1]

Young J., Weber R., Rickenbach M., Et al., Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study, Antivir Ther, 10, pp. 585-591, (2005)

[2]

Cohen C., Nieto-Cisneros L., Zala C., Et al., Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: A randomized multinational trial, Curr Med Res Opin, 21, pp. 1683-1692, (2005)

[3]

Wood R., Phanuphak P., Cahn P., Et al., Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir, J Acquir Immune Defic Syndr, 36, pp. 684-692, (2004)

[4]

Mobius U., Lubach-Ruitman M., Castro-Frenzel B., Et al., Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia, J Acquir Immune Defic Syndr, 39, pp. 174-180, (2005)

[5]

Johnson M., Grinsztejn B., Rodriguez C., Et al., 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures, AIDS, 20, pp. 711-718, (2006)

[6]

Rodriguez-French A., Boghossian J., Gray G.E., Et al., The NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients, J Acquir Immune Defic Syndr, 35, pp. 22-32, (2004)

[7]

Eron Jr. J., Yeni P., Gathe Jr. J., Et al., The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial, Lancet, 368, pp. 476-482, (2006)

[8]

Periard D., Telenti A., Sudre P., Et al., Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors, Circulation, 100, pp. 700-705, (1999)

[9]

Malan N., Krantz E., David N., Et al., Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089, 13th Conference on Retroviruses and Opportunistic Infections, (2006)

[10]

Gallant J.E., Staszewski S., Pozniak A.L., Et al., Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial, JAMA, 292, pp. 191-201, (2004)

← 1 2 3 4 5 6 7 →